VTYX

Ventyx Biosciences, Inc.

9.00 USD
+0.50 (+5.88%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Ventyx Biosciences, Inc. stock is up 287.93% since 30 days ago. The next earnings date is May 9, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 66.67% of the previous 2 March’s closed higher than February. In the last 10 Unusual Options Trades, there were 9 CALLs, 1 PUT. 0% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
01 Mar 18:06 15 Mar, 2024 7.50 CALL 100 4554
01 Mar 18:12 15 Mar, 2024 7.50 CALL 150 4554
01 Mar 19:10 15 Mar, 2024 7.50 CALL 187 4554
01 Mar 19:11 15 Mar, 2024 7.50 PUT 330 200
01 Mar 20:06 15 Mar, 2024 7.50 CALL 183 4554
01 Mar 20:58 15 Mar, 2024 7.50 CALL 100 4554
04 Mar 15:47 15 Mar, 2024 7.50 CALL 100 5930
04 Mar 17:23 15 Mar, 2024 7.50 CALL 140 5930
04 Mar 20:28 15 Mar, 2024 12.50 CALL 318 682
04 Mar 20:56 15 Mar, 2024 7.50 CALL 135 5930

About Ventyx Biosciences, Inc.

Ventyx Biosciences, Inc. develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis, inflammatory bowel disease, psoriatic arthritis, Crohn's disease, and lupus.